All News

The Weekly Dose: Clinical Updates on Cancer Detection, Cognitive Screening, CVD Prevention, Atopic Dermatitis Treatment
July 08, 2025

Discover essential clinical insights on Alzheimer disease screening in primary care, eczema treatments, and the latest in cancer detection and diet impacts on CHD risk.

New Data at IAS 2025 Underscore Real-World Success of Long-Acting Injectable HIV Therapies
July 08, 2025

New findings showcase the transformative impact of long-acting injectable therapies for effective HIV treatment and prevention.

5 Fall Prevention Tips for Your Older Adult Patients: Refresher for Primary Care
July 08, 2025

Exercise and strength/balance training are keys to protecting against falls, but careful assessments at each clinic visit may uncover other risks to address.

Body Fat Percentage Outperforms BMI in Predicting Mortality Risk in Young Adults: New Findings
July 08, 2025

Body fat percentage and waist circumference were both significantly associated with 15-year all-cause mortality while BMI had no significant association.

Lifestyle Interventions for Treatment and Remission of Prediabetes and T2D: There's a Guideline for That?
July 08, 2025

The American College of Lifestyle Medicine recently published "that guideline," and lead author Richard Rosenfeld, MD, MPH, MBA, says the timing was right.

Obesity and Type 2 Diabetes: Expert Shares 4 Pillars of Management
July 07, 2025

Caissa Troutman, MD, discusses how clinicians can tailor management plans to reduce risk of developing T2D in patients with obesity.

Clinic- and System-Level Factors Drive Racial Disparities in COVID-19 Antiviral Prescribing, Study Finds
July 07, 2025

A new study found racial disparities in COVID-19 antiviral prescribing, with clinic site, test type, and telehealth use explaining up to half the gap for Black and Latino patients.

Intranasal COVID-19 Vaccine Found Safe and Immunogenic in Open Label Phase 1 Clinical Trial
July 07, 2025

Among recipients of high-dose CVXGA, relative vaccine effectiveness was 67.8% against symptomatic COVID infection at a median 7.3 months post-vaccination.

Novel GLP-1/GLP-2 Agent Reduces Body Weight by Up to 8.3% in Phase 1b Obesity Trial
July 07, 2025

ADA 2025: Dapiglutide showed promising safety and weight loss results in a phase 1b trial, targeting obesity and inflammation with once-weekly dosing.

Apogee Hopes Raised by Phase 2 Data for APG777 to be a Best-In-Class for Atopic Dermatitis
July 07, 2025

The investigational IL-13 inhibitor showed topline EASI-75 of 66.9% and reduced injection frequency in part A of the APEX phase 2 clinical trial.